Plain-English translation of NCT05668962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thyroid Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called , when combined with radioactive iodine (a standard thyroid cancer treatment), can help people whose thyroid cancer has become resistant to radioactive iodine alone. The medication works by blocking a specific protein (RET) that is driving the cancer growth in certain patients. Researchers want to see if this combination approach can restore the cancer's ability to absorb radioactive iodine and stop the disease from progressing.
Some patients with advanced thyroid cancer stop responding to radioactive iodine treatment, which is normally very effective. This trial explores whether adding this medication might 'wake up' the cancer cells so they can absorb the radioactive iodine again, offering hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would take the medication for 4 weeks, and during the fourth week, you would receive a therapeutic dose of radioactive iodine. If your cancer shows signs of responding to this treatment, you may be offered a second 4-week cycle of the same combination. You will have screening visits to confirm you are eligible, regular check-in visits during treatment, and follow-up care for 2 years after joining the study to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States